Abstract: A method for detecting whether an amplification phase has occurred in an amplification in which a nucleic acid sequence is increased in a defined number of amplification cycles includes determining the intensity of a signal of the nucleic acid sequence after each amplification cycle and representing the determined intensity as a measurement point as a function of the amplification cycle. The method includes calculating a first regression line from a first measurement point recorded after a first amplification cycle to the determined starting point of the amplification phase; calculating a second regression line over all measurement points; comparing the first regression line to the second regression line regarding the dissimilarity of the first and second regression lines using a first statistical test, wherein a p-value is ascertained; and detecting whether an amplification phase has occurred based on whether the p-value is below or above a defined limit value.

Abstract: The present disclosure relates to a method for operating a multi-channel pipettor, comprising: creating an access plan having a plurality of transfer blocks, each comprising a source access and a destination access, wherein the creating includes: reading of position lists which contain the positions of all source and destination containers and assigning source containers to destination containers; performing a transfer analysis in which the source or destination accesses and the movements of the pipetting head and/or the container holders are determined by forming the difference between the current channel position and the source position or the destination position on the two-dimensional plane; and performing a transfer optimization, whereby the source or destination accesses and the movements of the pipetting head respectively required for the source or destination accesses are sorted into the transfer blocks; and operating the multi-channel pipettor on the basis of the created access plan.

Abstract: The present disclosure relates to a method for operating a multi-channel pipettor, comprising: creating an access plan having a plurality of transfer blocks, each comprising a source access and a destination access, wherein the creating includes: reading of position lists which contain the positions of all source and destination containers and assigning source containers to destination containers; performing a transfer analysis in which the source or destination accesses and the movements of the pipetting head and/or the container holders are determined by forming the difference between the current channel position and the source position or the destination position on the two-dimensional plane; and performing a transfer optimization, whereby the source or destination accesses and the movements of the pipetting head respectively required for the source or destination accesses are sorted into the transfer blocks; and operating the multi-channel pipettor on the basis of the created access plan.

Abstract: The invention discloses a method for identifying a subset of polynucleotides from an initial set of polynucleotides corresponding to the human genome for the in vitro determination of severity of the host response of a patient having a severe infectious and/or inflammatory condition, in a sample, a measuring device comprising a plurality of different gene probes which represent the entire human genome, the test persons, depending on their infectious and/or inflammatory status, are divided into at least two clinically determined phenotype groups, changes of the gene expression signals between the phenotype groups are compared statistically, and gene probes are selected based on the gene expression signals which have significantly changed statistically between at least two phenotype groups.

Abstract: The present invention relates to a novel form of the (?)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.

Abstract: The present invention relates to a novel form of the (?)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2 -pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.

Abstract: The present invention relates to the use of defined polynucleotides to form at least one multi-gene biomarker for producing a multiplex assay as a tool for in vitro detection and/or early detection and/or differentiation and/or progress monitoring and/or evaluation of pathophysiological conditions of a patient, the pathophysiological condition selected from the group consisting of: SIRS, sepsis and its degrees of severity; sepsis-like conditions, septic shock, bacteremia, infective/non-infectious multiorgan failure, early detection of these conditions; focus control, control of surgical rehabilitation of the infection focus; responders/non-responders for a specific therapy, treatment monitoring; distinction between infectious and non-infectious etiology of systemic reactions of the organism, such as SIRS, sepsis, postoperative complications, chronic and/or acute organ dysfunction, shock response, inflammatory response and/or trauma.

Abstract: The present invention relates to a novel form of the (?)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.

Abstract: The present invention relates to a novel form of the (?)-enantiomer of 5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.

Abstract: The present invention relates to a novel form of the (−)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.